My laboratory has focused on several areas of human immunology and virology, particularly in studying human immuno-pathology of chronic virus infections. My group was one of the first to use humanized mouse models to study HIV-1 or HBV/HCV infection and pathogenesis. My lab has identified novel virological and immunological mechanisms of HIV-1 and HBV pathogenesis. In recent years, my group has discovered and focused on the Plasmacytoid dendritic cells (pDC)-interferon-macrophage axis in the immuno-pathogenesis and therapy of chronic HIV & HBV infections.
IBBR Seminar Series
Microorganisms have been used for well over a century to experimentally unlock the mysteries metabolism and to better understand and control processes like fermentation. Much of what we know today about central metabolism was through simple, but ingenious, experimentation on yeast and bacteria. Much more recently, mammalian cells have been developed to treat diseases such as cancer. T-cells modified with chimeric antigen receptors (CAR-T), mesenchymal stem/stromal cells, and induced pluripotent stem cells (iPSC) all have potential for therapeutic applications.
Amino acids comprise structures of various sizes, ranging from a short chain of a peptide to complex macromolecular assemblies. By modifying residues within peptides and proteins or proteins that make up the assemblies, we can gain insight into the modification target’s native function or enhance its function. In this talk, I will describe how I have successfully used protein engineering approaches to modify the properties of targets of different sizes, including an antimicrobial peptide (small), a fluorescent protein (medium), and a protein shell assembly (large).